Summary:
Midwest Research Group is conducting a 6-week long phase 3 trial evaluating the efficacy, safety and tolerability of cariprazine in patients with bipolar I depression.
Qualified Participants Must:
• Be between 18 and 65 years of age
•
Currently meet the DSM-5 criteria for bipolar I disorder
•
Currently been depressed for at least 4 weeks
•
Be currently treated by a doctor or therapist
Qualified Participants May Receive:
Compensation,
Free medical evaluation,
Free medication, and
Free physician visits.